{
"description": "Medizininformatik Initiative - Modul Molekulares Tumorboard",
"_filename": "ImplementationGuide-mii-kerndatensatzmodul-molekulares-tumorboard.json",
"package_name": "de.medizininformatikinitiative.kerndatensatz.mtb",
"definition": {
"page": {
"page": [ ],
"title": "Table of Contents",
"nameUrl": "toc.html",
"generation": "html"
},
"resource": [ {
"name": "01.05.2023 Krankenkassenantrag Mirvetuximab soravtansine genehmigt",
"reference": {
"reference": "ClaimResponse/MII-EXA-MTB-Antwort-Kostenuebernahme-1"
},
"exampleCanonical": "https://www.medizininformatik-initiative.de/fhir/ext/modul-mtb/StructureDefinition/mii-pr-mtb-antwort-kostenuebernahme"
}, {
"name": "07.08.2023 Z3 Mirvetuximab soravtansine 6mg/kg KG, Wdh d22",
"reference": {
"reference": "MedicationStatement/MII-EXA-MTB-Systemische-Therapie-Medication-3"
},
"exampleCanonical": "https://www.medizininformatik-initiative.de/fhir/ext/modul-mtb/StructureDefinition/mii-pr-mtb-systemtherapie-medication-statement"
}, {
"name": "10.03.2023 Krankenkassenantrag gestellt Mirvetuximab soravtansine",
"reference": {
"reference": "Claim/MII-EXA-MTB-Antrag-Kostenuebernahme-1"
},
"exampleCanonical": "https://www.medizininformatik-initiative.de/fhir/ext/modul-mtb/StructureDefinition/mii-pr-mtb-antrag-kostenuebernahme"
}, {
"name": "12.10.2023 Z6 Mirvetuximab soravtansine 6mg/kg KG, Wdh d22",
"reference": {
"reference": "MedicationStatement/MII-EXA-MTB-Systemische-Therapie-Medication-6"
},
"exampleCanonical": "https://www.medizininformatik-initiative.de/fhir/ext/modul-mtb/StructureDefinition/mii-pr-mtb-systemtherapie-medication-statement"
}, {
"name": "16.07.2023 Z2 Mirvetuximab soravtansine 6mg/kg KG, Wdh d22",
"reference": {
"reference": "MedicationStatement/MII-EXA-MTB-Systemische-Therapie-Medication-2"
},
"exampleCanonical": "https://www.medizininformatik-initiative.de/fhir/ext/modul-mtb/StructureDefinition/mii-pr-mtb-systemtherapie-medication-statement"
}, {
"name": "20.01.2023 Molekulares Tumorboard:",
"reference": {
"reference": "CarePlan/MolekularesTumorboardSession-1"
},
"description": "1. Vorstellungsgrund: absehbare Ausschöpfung der leitliniengerechten Therapie\r\n2. Die MTB-Aufklärung vom 02.01.2025 liegt vor.\r\n3. Durchführung molekulare Diagnostik via SOP Ovar (inkl. IHC für Her2neu, Folat-Ra, Trop2) aus aktuellster Histologie (Aszitespunktion Z 230201/23) sowie TSO500 Panelsequenzierung inkl. HLA-Status.\r\n4. Studiencheck (inkl. QuickQueck Suche): Evaluation einer CLDN6 (Claudin-6)-Expression und darauf basierend eines möglichen Einschlusses in die Phase 1/2 CLDN6 CAR-T-Zell-Studie (Kohorte 2: Eierstockkrebs) mit CLDN6 RNA-LPX (PI Dr. Desuki, Mainz oder Prof. Ungerechts, Heidelberg, NCT 04503278, erste Ergebnisse publiziert unter PMID: 37872225 ). Einschluss prüfen in TEDOVA: OSE2101 (Neo-Epitop-Vakzin)+/- Pembrolizumab vs. BSC in Platin-sensitiven rez. Ov-CA (NCT04713514, PI Prof. Schochter, Ulm. platin-sensibles Rezidiv (=CR, PR oder SD), nach mind. 4 Zyklen Platin im Rezidiv und HLA-A2). \r\n5. Wiedervorstellung nach Eingang der Befunde.\r\n",
"exampleCanonical": "https://www.medizininformatik-initiative.de/fhir/ext/modul-mtb/StructureDefinition/mii-pr-mtb-therapieplan"
}, {
"name": "20.08.2023 CT T/A",
"reference": {
"reference": "Observation/MII-EXA-MTB-Response-Befund-1"
},
"exampleCanonical": "https://www.medizininformatik-initiative.de/fhir/ext/modul-mtb/StructureDefinition/mii-pr-mtb-response-befund"
}, {
"name": "20.09.2023 Z5 Mirvetuximab soravtansine 6mg/kg KG, Wdh d22",
"reference": {
"reference": "MedicationStatement/MII-EXA-MTB-Systemische-Therapie-Medication-5"
},
"exampleCanonical": "https://www.medizininformatik-initiative.de/fhir/ext/modul-mtb/StructureDefinition/mii-pr-mtb-systemtherapie-medication-statement"
}, {
"name": "22.10.2023 CT T/A",
"reference": {
"reference": "Observation/MII-EXA-MTB-Response-Befund-2"
},
"exampleCanonical": "https://www.medizininformatik-initiative.de/fhir/ext/modul-mtb/StructureDefinition/mii-pr-mtb-response-befund"
}, {
"name": "24.06.2023 - 12.10.2023 Mirvetuximab soravtansine",
"reference": {
"reference": "Procedure/MII-EXA-MTB-Systemische-Therapie-1"
},
"exampleCanonical": "https://www.medizininformatik-initiative.de/fhir/ext/modul-mtb/StructureDefinition/mii-pr-mtb-systemische-therapie"
}, {
"name": "24.06.2023 Z1 Mirvetuximab soravtansine 6mg/kg KG, Wdh d22",
"reference": {
"reference": "MedicationStatement/MII-EXA-MTB-Systemische-Therapie-Medication-1"
},
"exampleCanonical": "https://www.medizininformatik-initiative.de/fhir/ext/modul-mtb/StructureDefinition/mii-pr-mtb-systemtherapie-medication-statement"
}, {
"name": "29.08.2023 Z4 Mirvetuximab soravtansine 6mg/kg KG, Wdh d22",
"reference": {
"reference": "MedicationStatement/MII-EXA-MTB-Systemische-Therapie-Medication-4"
},
"exampleCanonical": "https://www.medizininformatik-initiative.de/fhir/ext/modul-mtb/StructureDefinition/mii-pr-mtb-systemtherapie-medication-statement"
}, {
"name": "A Clinical Study of the Safety and Effectiveness of an Investigational Cell Therapy Given With and Without an Investigational RNA-based Vaccine in Patients With Organ Tumors",
"reference": {
"reference": "ResearchStudy/mii-exa-mtb-study-cldn6"
},
"description": "This is a Phase I, FIH, open-label, multicenter, dose escalation trial with expansion cohorts to evaluate safety and preliminary efficacy of claudin 6 (CLDN6) chimeric antigen receptor T cells (CAR-T) with or without CLDN6 ribonucleic acid lipoplexes (RNA-LPX) in patients with CLDN6-positive relapsed or refractory advanced solid tumors.",
"exampleCanonical": "https://www.medizininformatik-initiative.de/fhir/ext/modul-mtb/StructureDefinition/mii-pr-mtb-studie"
}, {
"name": "Adavosertib",
"reference": {
"reference": "Medication/mii-exa-mtb-medication-adavosertib"
},
"description": "Medikament: Adavosertib",
"exampleBoolean": true
}, {
"name": "Adavosertib",
"reference": {
"reference": "MedicationRequest/mii-exa-mtb-medication-request-adavosertib"
},
"description": "Therapieempfehlung: Adavosertib",
"exampleCanonical": "https://www.medizininformatik-initiative.de/fhir/ext/modul-mtb/StructureDefinition/mii-pr-mtb-therapieempfehlung"
}, {
"name": "Adavosertib +/- Carboplatin",
"reference": {
"reference": "RequestGroup/mii-exa-mtb-request-group-adavosertib-carboplatin"
},
"description": "Therapieempfehlung Kombinationstherapie: Adavosertib +/- Carboplatin",
"exampleCanonical": "https://www.medizininformatik-initiative.de/fhir/ext/modul-mtb/StructureDefinition/mii-pr-mtb-therapieempfehlung-kombination"
}, {
"name": "Beispiel fuer eine Systemtherapie",
"reference": {
"reference": "Procedure/MII-EXA-MTB-Systemtherapie-Beispiel-1"
},
"exampleCanonical": "https://www.medizininformatik-initiative.de/fhir/ext/modul-mtb/StructureDefinition/mii-pr-mtb-systemische-therapie"
}, {
"name": "Beispiel fuer einen Antrag auf Kostenuebernahme",
"reference": {
"reference": "Claim/MII-EXA-MTB-Antrag-Kostenuebernahme-Beispiel-1"
},
"exampleCanonical": "https://www.medizininformatik-initiative.de/fhir/ext/modul-mtb/StructureDefinition/mii-pr-mtb-antrag-kostenuebernahme"
}, {
"name": "Beispiel fuer einen Follow-Up Procedure",
"reference": {
"reference": "ClinicalImpression/MII-EXA-MTB-Follow-Up-ClinicalImpression-Beispiel-1"
},
"exampleCanonical": "https://www.medizininformatik-initiative.de/fhir/ext/modul-mtb/StructureDefinition/mii-pr-mtb-follow-up-clinicalimpression"
}, {
"name": "Beispiel fuer einen GenomicStudy",
"reference": {
"reference": "Procedure/MII-EXA-MTB-GenomicStudy-1"
},
"exampleCanonical": "https://www.medizininformatik-initiative.de/fhir/ext/modul-mtb/StructureDefinition/mii-pr-mtb-genomic-study"
}, {
"name": "Beispiel fuer einen GenomicStudyAnalysis",
"reference": {
"reference": "Procedure/MII-EXA-MTB-GenomicStudyAnalysis-1"
},
"exampleCanonical": "https://www.medizininformatik-initiative.de/fhir/ext/modul-mtb/StructureDefinition/genomic-study-analysis"
}, {
"name": "Beispiel fuer einen Sequencer",
"reference": {
"reference": "Device/MII-EXA-MTB-Device-Sequencer-1"
},
"exampleBoolean": true
}, {
"name": "BioNTech Cell & Gene Therapies GmbH",
"reference": {
"reference": "Organization/mii-exa-mtb-study-sponsor-biontech"
},
"description": "Sponsor: BioNTech Cell & Gene Therapies GmbH",
"exampleBoolean": true
}, {
"name": "BioNTech Responsible Person",
"reference": {
"reference": "PractitionerRole/mii-exa-mtb-study-investigator-biontech"
},
"description": "Investigator: BioNTech Responsible Person, BioNTech SE",
"exampleBoolean": true
}, {
"name": "CA 125 Tumor Marker Observation 1",
"reference": {
"reference": "Observation/MTBObservationCA125-1"
},
"description": "22.04.2022 CA 125 42,3 IU/ml",
"exampleBoolean": true
}, {
"name": "CA 125 Tumor Marker Observation 2",
"reference": {
"reference": "Observation/MTBObservationCA125-2"
},
"description": "18.07.2022 CA 125 45,8 IU/ml",
"exampleBoolean": true
}, {
"name": "CA 125 Tumor Marker Observation 3",
"reference": {
"reference": "Observation/MTBObservationCA125-3"
},
"description": "24.10.2022 CA 125 49,7 IU/ml",
"exampleBoolean": true
}, {
"name": "CA 125 Tumor Marker Observation 4",
"reference": {
"reference": "Observation/MTBObservationCA125-4"
},
"description": "27.12.2022 CA 125 67,2 IU/ml",
"exampleBoolean": true
}, {
"name": "CA 125 Tumor Marker Observation 5",
"reference": {
"reference": "Observation/MTBObservationCA125-5"
},
"description": "24.03.2023 CA 125 43,7 IU/ml",
"exampleBoolean": true
}, {
"name": "CA 125 Tumor Marker Observation 6",
"reference": {
"reference": "Observation/MTBObservationCA125-6"
},
"description": "20.06.2023 CA 125 78,2 IU/ml",
"exampleBoolean": true
}, {
"name": "Camonsertib",
"reference": {
"reference": "Medication/mii-exa-mtb-medication-camonsertib"
},
"description": "Medikament: Camonsertib",
"exampleBoolean": true
}, {
"name": "Camonsertib",
"reference": {
"reference": "MedicationRequest/mii-exa-mtb-medication-request-camonsertib"
},
"description": "Therapieempfehlung: Camonsertib",
"exampleCanonical": "https://www.medizininformatik-initiative.de/fhir/ext/modul-mtb/StructureDefinition/mii-pr-mtb-therapieempfehlung"
}, {
"name": "Carboplatin",
"reference": {
"reference": "MedicationRequest/mii-exa-mtb-medication-request-carboplatin"
},
"description": "Therapieempfehlung: Carboplatin",
"exampleCanonical": "https://www.medizininformatik-initiative.de/fhir/ext/modul-mtb/StructureDefinition/mii-pr-mtb-therapieempfehlung"
}, {
"name": "CCNE1",
"reference": {
"reference": "ResearchStudy/mii-exa-mtb-study-ccne1"
},
"description": "Studie: CCNE1 ampl. OvCA",
"exampleCanonical": "https://www.medizininformatik-initiative.de/fhir/ext/modul-mtb/StructureDefinition/mii-pr-mtb-studie"
}, {
"name": "CCNE1",
"reference": {
"reference": "ServiceRequest/mii-exa-mtb-study-request-ccne1"
},
"description": "Studieneinschlussempfehlung: CCNE1 ampl. OvCA",
"exampleCanonical": "https://www.medizininformatik-initiative.de/fhir/ext/modul-mtb/StructureDefinition/mii-pr-mtb-studieneinschluss-anfrage"
}, {
"name": "CCNE1 Einfache Variante 2",
"reference": {
"reference": "Observation/mii-exa-mtb-kim-musterperson-CNVariante-CCNE1"
},
"description": "Kopienzahlveränderung bei einer CCNE1-Mutation",
"exampleCanonical": "https://www.medizininformatik-initiative.de/fhir/ext/modul-mtb/StructureDefinition/mii-pr-mtb-copy-number-variant"
}, {
"name": "Cobimetinib",
"reference": {
"reference": "Medication/mii-exa-mtb-medication-cobimetinib"
},
"description": "Medikament: Cobimetinib",
"exampleBoolean": true
}, {
"name": "Cobimetinib",
"reference": {
"reference": "MedicationRequest/mii-exa-mtb-medication-request-cobimetinib"
},
"description": "Therapieempfehlung: Cobimetinib, Priorität: 6, Evidenzgrad: m3",
"exampleCanonical": "https://www.medizininformatik-initiative.de/fhir/ext/modul-mtb/StructureDefinition/mii-pr-mtb-therapieempfehlung"
}, {
"name": "Cool",
"reference": {
"reference": "Device/MII-EXA-MTB-Device-SequencingKit-1"
},
"exampleBoolean": true
}, {
"name": "Einwilligung zur MTB-Besprechung Kim Musterperson",
"reference": {
"reference": "Consent/mii-exa-mtb-kim-musterperson-aufklaerung"
},
"description": "Einwilligung von Kim Musterperson zur Besprechung im Molekularen Tumorboard vom 02.01.2023",
"exampleBoolean": true
}, {
"name": "ExampleDefinition",
"reference": {
"reference": "Device/MII-EXA-MTB-Device-LibraryPreparation-Kit-1"
},
"exampleBoolean": true
}, {
"name": "Follow-Up Prozess zur Überprüfung der durchgeführten Therapien & Kostenübernahmen",
"reference": {
"reference": "ClinicalImpression/MII-EXA-MTB-Follow-Up-ClinicalImpression-1"
},
"exampleCanonical": "https://www.medizininformatik-initiative.de/fhir/ext/modul-mtb/StructureDefinition/mii-pr-mtb-follow-up-clinicalimpression"
}, {
"name": "Genomic Study Analysis",
"reference": {
"reference": "StructureDefinition/genomic-study-analysis"
},
"description": "A genomic study analysis is a component of a genomic study.",
"exampleBoolean": false
}, {
"name": "Lunresertib",
"reference": {
"reference": "Medication/mii-exa-mtb-medication-lunresertib"
},
"description": "Medikament: Lunresertib",
"exampleBoolean": true
}, {
"name": "Lunresertib",
"reference": {
"reference": "MedicationRequest/mii-exa-mtb-medication-request-lunresertib"
},
"description": "Therapieempfehlung: Lunresertib",
"exampleCanonical": "https://www.medizininformatik-initiative.de/fhir/ext/modul-mtb/StructureDefinition/mii-pr-mtb-therapieempfehlung"
}, {
"name": "Lunresertib + Camonsertib",
"reference": {
"reference": "RequestGroup/mii-exa-mtb-request-group-lunresertib-camonsertib"
},
"description": "Therapieempfehlung Kombinationstherapie: Lunresertib + Camonsertib, Priorität: 5, Evidenzgrad: m1B",
"exampleCanonical": "https://www.medizininformatik-initiative.de/fhir/ext/modul-mtb/StructureDefinition/mii-pr-mtb-therapieempfehlung-kombination"
}, {
"name": "MII CS Antrag Kostenuebernahme Antragsstadium",
"reference": {
"reference": "CodeSystem/mii-cs-mtb-antrag-kostenuebernahme-antragsstadium"
},
"description": "Codesystem zum Stadium des Antrags zur Kostenuebernahme",
"exampleBoolean": false
}, {
"name": "MII CS Antwort Kostenuebernahme Entscheidung",
"reference": {
"reference": "CodeSystem/mii-cs-mtb-antwort-kostenuebernahme-entscheidung"
},
"description": "Codesystem zum Status der Antwort zur Kostenuebernahme",
"exampleBoolean": false
}, {
"name": "MII CS Auftrag Begründung",
"reference": {
"reference": "CodeSystem/mii-cs-mtb-auftrag-begruendung"
},
"description": "Begründung zum Auftrag zur (erneuten) Untersuchung oder Diagnostik",
"exampleBoolean": false
}, {
"name": "MII CS Bestimmungsmethode Tumorzellgehalt",
"reference": {
"reference": "CodeSystem/mii-cs-mtb-bestimmungsmethode-tumorzellgehalt"
},
"description": "Angewandte Methode zur Bestimmung des Tumorzellgehalts",
"exampleBoolean": false
}, {
"name": "MII CS Dosisdichte",
"reference": {
"reference": "CodeSystem/mii-cs-mtb-dosisdichte"
},
"description": "Codesystem für die Dosisdichte einer Systemtheraptie",
"exampleBoolean": false
}, {
"name": "MII CS Empfehlung Evidenzgrad",
"reference": {
"reference": "CodeSystem/mii-cs-mtb-empfehlung-evidenzgrad-nct"
},
"description": "Evidenzgrad einer Empfehlung",
"exampleBoolean": false
}, {
"name": "MII CS Empfehlung Evidenzgrad Zusatzverweis",
"reference": {
"reference": "CodeSystem/mii-cs-mtb-empfehlung-evidenzgrad-zusatzverweis"
},
"description": "Zusatzverweis zum Evidenzgrad einer Empfehlung",
"exampleBoolean": false
}, {
"name": "MII CS Empfehlung Status Begründung",
"reference": {
"reference": "CodeSystem/mii-cs-mtb-empfehlung-status-begruendung"
},
"description": "Begründung bei fehlender Empfehlung im MTB-Beschluss",
"exampleBoolean": false
}, {
"name": "MII CS Follow-Up Grund Nicht-Umsetzung",
"reference": {
"reference": "CodeSystem/mii-cs-mtb-follow-up-grund-nicht-umsetzung"
},
"description": "Codesystem zum Follow-Up Grund Nicht-Umsetzung",
"exampleBoolean": false
}, {
"name": "MII CS Follow-Up Status",
"reference": {
"reference": "CodeSystem/mii-cs-mtb-follow-up-status"
},
"description": "Codesystem zum Follow-Up Status",
"exampleBoolean": false
}, {
"name": "MII CS Genomic Analysis Method Type",
"reference": {
"reference": "CodeSystem/mii-cs-mtb-genomic-analysis-method-type"
},
"description": "Codesystem, welches die verwendeten NGS-Methodiken gemäß dnpm-Kodierung high-level auflistet",
"exampleBoolean": false
}, {
"name": "MII CS GenomicAnalysis DeviceType",
"reference": {
"reference": "CodeSystem/mii-cs-mtb-genomicanalysis-devicefunction"
},
"description": "Codesystem, welches verschiedene Molekulare Biomarker enthäldie verschiedenen Arten von Geräten und Produkten enthält, die im Rahmen einer NGS-Analyse genutzt werden",
"exampleBoolean": false
}, {
"name": "MII CS Kostenuebernahme Ablehnungsgrund",
"reference": {
"reference": "CodeSystem/mii-cs-mtb-kostenuebernahme-ablehnungsgrund"
},
"description": "Codesystem zum Grund der Ablehnung der Kostenuebernahme",
"exampleBoolean": false
}, {
"name": "MII CS Leitlinienbehandlung Status",
"reference": {
"reference": "CodeSystem/mii-cs-mtb-leitlinienbehandlung-status"
},
"description": "Status der Behandlung nach Leitlinie",
"exampleBoolean": false
}, {
"name": "MII CS Molekulare Biomarker",
"reference": {
"reference": "CodeSystem/mii-cs-mtb-molekulare-biomarker"
},
"description": "Codesystem, welches verschiedene Molekulare Biomarker enthält, die nicht in anderen offenen semantischen Standards wie LOINC oder SNOMED-CT abgebildet sind",
"exampleBoolean": false
}, {
"name": "MII CS Response Befund Beurteilung",
"reference": {
"reference": "CodeSystem/mii-cs-mtb-response-befund-beurteilung"
},
"description": "Codesystem für die Beurteilung des Response Befund",
"exampleBoolean": false
}, {
"name": "MII CS Zulassungsstatus",
"reference": {
"reference": "CodeSystem/mii-cs-mtb-zulassungsstatus"
},
"description": "Angabe zum Zulassungsstatus",
"exampleBoolean": false
}, {
"name": "MII EX MTB Antrag Kostenuebernahme Antragsstadium",
"reference": {
"reference": "StructureDefinition/mii-ex-mtb-antrag-kostenuebernahme-antragsstadium"
},
"description": "Stadium des Antrags zur Kostenuebernahme",
"exampleBoolean": false
}, {
"name": "MII EX MTB Antwort Kostenuebernahme Ablehnungsgrund",
"reference": {
"reference": "StructureDefinition/mii-ex-mtb-antwort-kostenuebernahme-ablehnungsgrund"
},
"description": "Ablehnungsgrund des Antrags auf Kostenuebernahme",
"exampleBoolean": false
}, {
"name": "MII EX MTB Antwort Kostenuebernahme Entscheidung",
"reference": {
"reference": "StructureDefinition/mii-ex-mtb-antwort-kostenuebernahme-entscheidung"
},
"description": "Entscheidung zum Antrag zur Kostenuebernahme",
"exampleBoolean": false
}, {
"name": "MII EX MTB Diagnose",
"reference": {
"reference": "StructureDefinition/mii-ex-mtb-diagnose"
},
"description": "Onkologische Diagnose",
"exampleBoolean": false
}, {
"name": "MII EX MTB Empfehlung Evidenzgraduierung",
"reference": {
"reference": "StructureDefinition/mii-ex-mtb-empfehlung-evidenzgraduierung"
},
"description": "Evidenzgraduierung der (einzelnen) Empfehlung",
"exampleBoolean": false
}, {
"name": "MII EX MTB Empfehlung Priorität",
"reference": {
"reference": "StructureDefinition/mii-ex-mtb-empfehlung-prioritaet"
},
"description": "Priorität der (einzelnen) Empfehlung",
"exampleBoolean": false
}, {
"name": "MII EX MTB Empfehlung Publikation",
"reference": {
"reference": "StructureDefinition/mii-ex-mtb-empfehlung-publikation"
},
"description": "Verweis auf Publikation der (einzelnen) Empfehlung",
"exampleBoolean": false
}, {
"name": "MII EX MTB Leitlinie Dokumentation",
"reference": {
"reference": "StructureDefinition/mii-ex-mtb-leitlinie-dokumentation"
},
"description": "Dokumentation zur Leitlinien-konformen Umsetzung der Prozedur",
"exampleBoolean": false
}, {
"name": "MII EX MTB Leitlinienbehandlung Status",
"reference": {
"reference": "StructureDefinition/mii-ex-mtb-leitlinienbehandlung-status"
},
"description": "Status der Behandlung nach Leitlinie",
"exampleBoolean": false
}, {
"name": "MII EX MTB NGS Bericht Metadaten",
"reference": {
"reference": "StructureDefinition/mii-ex-mtb-ngs-bericht-metadaten"
},
"description": "Metadaten des NGS-Berichts",
"exampleBoolean": false
}, {
"name": "MII EX MTB NGS Bericht QC",
"reference": {
"reference": "StructureDefinition/mii-ex-mtb-ngs-bericht-qc"
},
"description": "QC des NGS-Berichts",
"exampleBoolean": false
}, {
"name": "MII EX MTB Therapielinie",
"reference": {
"reference": "StructureDefinition/mii-ex-mtb-therapielinie"
},
"description": "Angabe der Therapielinie",
"exampleBoolean": false
}, {
"name": "MII EX MTB Zulassungsstatus",
"reference": {
"reference": "StructureDefinition/mii-ex-mtb-zulassungsstatus"
},
"description": "Zulassungsstatus der Leitlinientherapie",
"exampleBoolean": false
}, {
"name": "MII LM Molekulares Tumorboard",
"reference": {
"reference": "StructureDefinition/mii-lm-mtb"
},
"description": "MII Logical Model Modul Molekulares Tumorboard",
"exampleBoolean": false
}, {
"name": "MII NS MTB NCT",
"reference": {
"reference": "NamingSystem/mii-ns-mtb-nct"
},
"description": "NamingSystem für Identifikatoren des Nationalen Centrums für Tumorerkrankungen (NCT)",
"exampleBoolean": false
}, {
"name": "MII NS Studie DRKS",
"reference": {
"reference": "NamingSystem/mii-ns-studie-drks"
},
"description": "NamingSystem für Identifikatoren des Deutschen Register Klinischer Studien (DRKS)",
"exampleBoolean": false
}, {
"name": "MII NS Studie EudraCT",
"reference": {
"reference": "NamingSystem/mii-ns-studie-eudract"
},
"description": "NamingSystem für Identifikatoren der European Union Drug Regulating Authorities Clinical Trials (EudraCT)",
"exampleBoolean": false
}, {
"name": "MII PR Biomarker Her2 Status",
"reference": {
"reference": "StructureDefinition/mii-pr-mtb-biomarker-her2-status"
},
"description": "...",
"exampleBoolean": false
}, {
"name": "MII PR MTB Antrag Kostenuebernahme",
"reference": {
"reference": "StructureDefinition/mii-pr-mtb-antrag-kostenuebernahme"
},
"description": "Antrag Kostenübernahme",
"exampleBoolean": false
}, {
"name": "MII PR MTB Anwort Kostenuebernahme",
"reference": {
"reference": "StructureDefinition/mii-pr-mtb-antwort-kostenuebernahme"
},
"description": "Antwort auf Antrag Kostenübernahme",
"exampleBoolean": false
}, {
"name": "MII PR MTB Behandlungsepisode",
"reference": {
"reference": "StructureDefinition/mii-pr-mtb-behandlungsepisode"
},
"description": "Aktueller Krankheitszustand und bisherige Behandlungsmaßnahmen",
"exampleBoolean": false
}, {
"name": "MII PR MTB Biopsie Auftrag",
"reference": {
"reference": "StructureDefinition/mii-pr-mtb-biopsie-auftrag"
},
"description": "Auftrag zur (erneuten) Biopsie",
"exampleBoolean": false
}, {
"name": "MII PR MTB BRCAness",
"reference": {
"reference": "StructureDefinition/mii-pr-mtb-brcaness"
},
"description": "Beschreibt die BRCAness, also wie sehr ein Tumor ein Verhalten zeigt, welches BRCA1- oder BRCA2-Mutationen entspricht. Die BRCAness ist ein Indikator für die Wirksamkeit von PARP-Inhibitoren.",
"exampleBoolean": false
}, {
"name": "MII PR MTB Clinical Impresssion",
"reference": {
"reference": "StructureDefinition/mii-pr-mtb-follow-up-clinicalimpression"
},
"description": "Follow-Up nach DNPM ",
"exampleBoolean": false
}, {
"name": "MII PR MTB Copy Number Variant",
"reference": {
"reference": "StructureDefinition/mii-pr-mtb-copy-number-variant"
},
"description": "Copy Number Variant (CNV)",
"exampleBoolean": false
}, {
"name": "MII PR MTB Diagnose Primärtumor",
"reference": {
"reference": "StructureDefinition/mii-pr-mtb-diagnose-primaertumor"
},
"description": "Diagnose zum Primärtumor",
"exampleBoolean": false
}, {
"name": "MII PR MTB Diagnostische Implikation",
"reference": {
"reference": "StructureDefinition/mii-pr-mtb-diagnostische-implikation"
},
"description": "Beschreibt den Zusammenhang zwischen einem oder mehreren Genotyp/Haplotyp/Varianten und Beweisen für oder gegen eine bestimmte Krankheit.",
"exampleBoolean": false
}, {
"name": "MII PR MTB DNA Fusion",
"reference": {
"reference": "StructureDefinition/mii-pr-mtb-dna-fusion"
},
"description": "DNA-Fusion",
"exampleBoolean": false
}, {
"name": "MII PR MTB Einfache Variante",
"reference": {
"reference": "StructureDefinition/mii-pr-mtb-einfache-variante"
},
"description": "Beschreibt eine gefundene genetische Variante.",
"exampleBoolean": false
}, {
"name": "MII PR MTB Genomic Study",
"reference": {
"reference": "StructureDefinition/mii-pr-mtb-genomic-study"
},
"description": "Genomic Study beinhaltet und verweist über GenomicStudyAnalysis auf Details zu den einzelnen Untersuchungen einer NGS-Untersuchung (Sequenzierung, Variant Calling, CNV-Analyse, Fusions-Analysen etc.)",
"exampleBoolean": false
}, {
"name": "MII PR MTB Histologie-Evaluation Auftrag",
"reference": {
"reference": "StructureDefinition/mii-pr-mtb-histologie-evaluation-auftrag"
},
"description": "Auftrag zur (erneuten) Histologie-Evaluation",
"exampleBoolean": false
}, {
"name": "MII PR MTB HRD Score",
"reference": {
"reference": "StructureDefinition/mii-pr-mtb-hrd-score"
},
"description": "Der HRD-Score, welcher den Grad der homologen Rekombinationsdefizienz bei Zellen beschreibt.",
"exampleBoolean": false
}, {
"name": "MII PR MTB Human-genetische Beratung Auftrag",
"reference": {
"reference": "StructureDefinition/mii-pr-mtb-humangenetische-beratung-auftrag"
},
"description": "Auftrag zur (erneuten) Human-genetischen Beratung",
"exampleBoolean": false
}, {
"name": "MII PR MTB Immunohistochemistry",
"reference": {
"reference": "StructureDefinition/mii-pr-mtb-histochemistry"
},
"description": "Immunhistorchemistry report",
"exampleBoolean": false
}, {
"name": "MII PR MTB Immunohistochemistry",
"reference": {
"reference": "StructureDefinition/mii-pr-mtb-immunohistochemistry"
},
"description": "Immunhistorchemistry report",
"exampleBoolean": false
}, {
"name": "MII PR MTB Immunohistochemistry",
"reference": {
"reference": "StructureDefinition/mii-pr-mtb-immunohistochemistry-her2"
},
"description": "Immunhistrchemistry report",
"exampleBoolean": false
}, {
"name": "MII PR MTB Immunohistochemistry",
"reference": {
"reference": "StructureDefinition/mii-pr-mtb-immunohistochemistry-pdl1"
},
"description": "Immunhistorchemistry report",
"exampleBoolean": false
}, {
"name": "MII PR MTB Immunohistochemistry",
"reference": {
"reference": "StructureDefinition/mii-pr-mtb-immunohistochemistry-mmr-msi"
},
"description": "Immunhistorchemistry report",
"exampleBoolean": false
}, {
"name": "MII PR MTB In Situ Hybridization",
"reference": {
"reference": "StructureDefinition/mii-pr-mtb-insituhybridization-her2"
},
"description": "In Situ Hybridization report",
"exampleBoolean": false
}, {
"name": "MII PR MTB In Situ Hybridization",
"reference": {
"reference": "StructureDefinition/mii-pr-mtb-insituhybridization"
},
"description": "Molekularer Biomarker - In Situ Hybridization Profil",
"exampleBoolean": false
}, {
"name": "MII PR MTB Mikrosatelliteninstabilität",
"reference": {
"reference": "StructureDefinition/mii-pr-mtb-mikrosatelliteninstabilitaet"
},
"description": "Beschreibt die Neigung zu Mutationen aufgrund einer gestörten Fehlpaarungsreparatur (DNA mismatch repair, MMR).",
"exampleBoolean": false
}, {
"name": "MII PR MTB Molecular Pathology Report",
"reference": {
"reference": "StructureDefinition/mii-pr-mtb-molecular-pathology-report"
},
"description": "Molecular pathology report",
"exampleBoolean": false
}, {
"name": "MII PR MTB Molekularer Biomarker",
"reference": {
"reference": "StructureDefinition/mii-pr-mtb-molekularer-biomarker"
},
"description": "Stellt einen gefundenden Biomarker dar. Das Profil ist auf Basis von https://build.fhir.org/ig/HL7/genomics-reporting/StructureDefinition-molecular-biomarker.html nachgebaut.",
"exampleBoolean": false
}, {
"name": "MII PR MTB Mutationslast",
"reference": {
"reference": "StructureDefinition/mii-pr-mtb-mutationslast"
},
"description": "Beschreibt die Gesamtzahl von in Krebszellen gefundenen Mutationen pro 1 Mio. Basen.",
"exampleBoolean": false
}, {
"name": "MII PR MTB NGS-Bericht",
"reference": {
"reference": "StructureDefinition/mii-pr-mtb-ngs-bericht"
},
"description": "NGS-Bericht zu einer Probe",
"exampleBoolean": false
}, {
"name": "MII PR MTB Oncotree Klassifikation",
"reference": {
"reference": "StructureDefinition/mii-pr-mtb-oncotree"
},
"description": "Grad des Tumors nach MSKCC Oncotree Klassifikation",
"exampleBoolean": false
}, {
"name": "MII PR MTB Response Befund",
"reference": {
"reference": "StructureDefinition/mii-pr-mtb-response-befund"
},
"description": "Response Beurteilung nach DNPM",
"exampleBoolean": false
}, {
"name": "MII PR MTB RNA Fusion",
"reference": {
"reference": "StructureDefinition/mii-pr-mtb-rna-fusion"
},
"description": "RNA-Fusion",
"exampleBoolean": false
}, {
"name": "MII PR MTB RNA Seq",
"reference": {
"reference": "StructureDefinition/mii-pr-mtb-rna-seq"
},
"description": "RNA Seq",
"exampleBoolean": false
}, {
"name": "MII PR MTB Studie",
"reference": {
"reference": "StructureDefinition/mii-pr-mtb-studie"
},
"description": "Onkologische Studie",
"exampleBoolean": false
}, {
"name": "MII PR MTB Studieneinschluss Anfrage",
"reference": {
"reference": "StructureDefinition/mii-pr-mtb-studieneinschluss-anfrage"
},
"description": "Anfrage zum Studieneinschluss",
"exampleBoolean": false
}, {
"name": "MII PR MTB Systemische Therapie",
"reference": {
"reference": "StructureDefinition/mii-pr-mtb-systemische-therapie"
},
"description": "Systemische Therapie im Follow-Up nach Abschluss des MTB",
"exampleBoolean": false
}, {
"name": "MII PR MTB Systemische Vortherapie",
"reference": {
"reference": "StructureDefinition/mii-pr-mtb-systemische-vortherapie"
},
"description": "Systemische Vortherapie zum Molekularen Tumorboard",
"exampleBoolean": false
}, {
"name": "MII PR MTB Systemtherapie Medication Statement",
"reference": {
"reference": "StructureDefinition/mii-pr-mtb-systemtherapie-medication-statement"
},
"description": "Medication Statement zur MTB-Systemtherapie mit Wirkstoff und Dosis",
"exampleBoolean": false
}, {
"name": "MII PR MTB Therapieempfehlung Kombinationstherapie",
"reference": {
"reference": "StructureDefinition/mii-pr-mtb-therapieempfehlung-kombination"
},
"description": "Therapieempfehlung für eine medikamentöse Kombinationstherapie",
"exampleBoolean": false
}, {
"name": "MII PR MTB Therapieempfehlung Systemische Therapie",
"reference": {
"reference": "StructureDefinition/mii-pr-mtb-therapieempfehlung"
},
"description": "Therapieempfehlung für eine medikamentöse Systemische Therapie",
"exampleBoolean": false
}, {
"name": "MII PR MTB Therapieplan",
"reference": {
"reference": "StructureDefinition/mii-pr-mtb-therapieplan"
},
"description": "Therapieplan gemäß Beschluss des Molekularen Tumorboards",
"exampleBoolean": false
}, {
"name": "MII PR MTB Tumorausbreitung",
"reference": {
"reference": "StructureDefinition/mii-pr-mtb-tumorausbreitung"
},
"description": "Angabe zur Tumorausbreitung",
"exampleBoolean": false
}, {
"name": "MII PR MTB Tumorzellgehalt",
"reference": {
"reference": "StructureDefinition/mii-pr-mtb-tumorzellgehalt"
},
"description": "Bestimmter Tumorzellgehalt",
"exampleBoolean": false
}, {
"name": "MII PR MTB WHO Grad Tumor ZNS",
"reference": {
"reference": "StructureDefinition/mii-pr-mtb-who-grad-tumor-zns"
},
"description": "Grad des Tumors nach WHO Klassifikation der Tumoren des zentralen Nervensystems (ZNS)",
"exampleBoolean": false
}, {
"name": "MII VS Abbruchsgrund",
"reference": {
"reference": "ValueSet/mii-vs-mtb-abbruchsgrund"
},
"description": "ValueSet zum Abbruchsgrund",
"exampleBoolean": false
}, {
"name": "MII VS Antrag Kostenuebernahme Antragsstadium",
"reference": {
"reference": "ValueSet/mii-vs-mtb-antrag-kostenuebernahme-antragsstadium"
},
"description": "ValueSet zum Stadium des Antrags zur Kostenuebernahme",
"exampleBoolean": false
}, {
"name": "MII VS Antwort Kostenuebernahme Status",
"reference": {
"reference": "ValueSet/mii-vs-mtb-antwort-kostenuebernahme-status"
},
"description": "ValueSet zum Status der Antwort auf den Antrags zur Kostenuebernahme",
"exampleBoolean": false
}, {
"name": "MII VS Auftrag Begründung",
"reference": {
"reference": "ValueSet/mii-vs-mtb-auftrag-begruendung"
},
"description": "ValueSet für Begründung zum Auftrag zur (erneuten) Untersuchung oder Diagnostik",
"exampleBoolean": false
}, {
"name": "MII VS Bestimmungsmethode Tumorzellgehalt",
"reference": {
"reference": "ValueSet/mii-vs-mtb-bestimmungsmethode-tumorzellgehalt"
},
"description": "ValueSet für Angewandte Methode zur Bestimmung des Tumorzellgehalts",
"exampleBoolean": false
}, {
"name": "MII VS Dosisdichte",
"reference": {
"reference": "ValueSet/mii-vs-mtb-dosisdichte"
},
"description": "ValueSet zur Dosisdichte",
"exampleBoolean": false
}, {
"name": "MII VS Empfehlung Evidenzgrad",
"reference": {
"reference": "ValueSet/mii-vs-mtb-empfehlung-evidenzgrad"
},
"description": "ValueSet für den Evidenzgrad einer Empfehlung",
"exampleBoolean": false
}, {
"name": "MII VS Empfehlung Evidenzgrad Zusatzverweis",
"reference": {
"reference": "ValueSet/mii-vs-mtb-empfehlung-evidenzgrad-zusatzverweis"
},
"description": "ValueSet für den Zusatzverweis zum Evidenzgrad einer Empfehlung",
"exampleBoolean": false
}, {
"name": "MII VS Empfehlung Status Begründung",
"reference": {
"reference": "ValueSet/mii-vs-mtb-empfehlung-status-begruendung"
},
"description": "ValueSet für Begründung bei fehlender Empfehlung im MTB-Beschluss",
"exampleBoolean": false
}, {
"name": "MII VS Follow-Up Grund Nicht-Umsetzung",
"reference": {
"reference": "ValueSet/mii-vs-mtb-follow-grund-nicht-umsetzung"
},
"description": "ValueSet zum Follow-Up Grund Nicht-Umsetzung",
"exampleBoolean": false
}, {
"name": "MII VS Follow-Up Status",
"reference": {
"reference": "ValueSet/mii-vs-mtb-follow-up-status"
},
"description": "ValueSet zum Follow-Up Status",
"exampleBoolean": false
}, {
"name": "MII VS Genomic Analysis Method Type",
"reference": {
"reference": "ValueSet/mii-vs-mtb-genomic-analysis-method-type"
},
"description": "ValueSet, dass die ursprünglich vom HL7 Clinical Genomics vorgeschlagenen Antwortmöglichkeiten für Genomic Study Analysis Method Type mit dem vom dnpm dekalrierten Antwortspektrum vereint",
"exampleBoolean": false
}, {
"name": "MII VS Kostenuebernahme Ablehnungsgrund",
"reference": {
"reference": "ValueSet/mii-vs-mtb-kostenuebernahme-ablehnungsgrund"
},
"description": "ValueSet zum Grund der Ablehnung des Antrags zur Kostenuebernahme",
"exampleBoolean": false
}, {
"name": "MII VS Leitlinienbehandlung Status",
"reference": {
"reference": "ValueSet/mii-vs-mtb-leitlinienbehandlung-status"
},
"description": "ValueSet zum Status der Behandlung nach Leitlinie",
"exampleBoolean": false
}, {
"name": "MII VS Molekulare Biomarker",
"reference": {
"reference": "ValueSet/mii-vs-mtb-immunohistochemistry-targets"
},
"description": "ValueSet zum CS Molekulare Biomarker",
"exampleBoolean": false
}, {
"name": "MII VS Molekulare Biomarker",
"reference": {
"reference": "ValueSet/mii-vs-mtb-molekulare-biomarker"
},
"description": "ValueSet zum CS Molekulare Biomarker",
"exampleBoolean": false
}, {
"name": "MII VS MTB Antrag Kostenuebernahme",
"reference": {
"reference": "ValueSet/mii-vs-mtb-antrag-kostenuebernahme"
},
"description": "MII Logical Model Modul Molekulares Tumorboard",
"exampleBoolean": false
}, {
"name": "MII VS MTB Systemtherapie Status",
"reference": {
"reference": "ValueSet/mii-vs-mtb-systemische-therapie-status"
},
"description": "Einschränkung der Status für Systemtherapie",
"exampleBoolean": false
}, {
"name": "MII VS OncoTree ValueSet",
"reference": {
"reference": "ValueSet/mii-vs-mtb-oncotree"
},
"description": "ValueSet der MSKCC OncoTree Klassifikationen",
"exampleBoolean": false
}, {
"name": "MII VS Response Befund Beurteilung",
"reference": {
"reference": "ValueSet/mii-vs-mtb-response-befund-beurteilung"
},
"description": "ValueSet Response Befund Beurteilung",
"exampleBoolean": false
}, {
"name": "MII VS Tumorausbreitung",
"reference": {
"reference": "ValueSet/mii-vs-mtb-tumorausbreitung"
},
"description": "ValueSet zur Angabe der Tumorausbreitung",
"exampleBoolean": false
}, {
"name": "MII VS WHO Grad Tumor ZNS",
"reference": {
"reference": "ValueSet/mii-vs-mtb-who-grad-tumor-zns"
},
"description": "ValueSet zum Grad eines Tumors nach WHO-Klassifikation der Tumoren des zentralen Nervensystems",
"exampleBoolean": false
}, {
"name": "MII VS Zulassungsstatus",
"reference": {
"reference": "ValueSet/mii-vs-mtb-zulassungsstatus"
},
"description": "ValueSet zum Zulassungsstatus",
"exampleBoolean": false
}, {
"name": "mii-exa-mtb-medikation-dabrafenib",
"reference": {
"reference": "Medication/mii-exa-mtb-medikation-dabrafenib"
},
"description": "Dabrafenib (Dabrafenib/Trametinib-Kombinationstherapie)",
"exampleBoolean": true
}, {
"name": "mii-exa-mtb-medikation-trametinib",
"reference": {
"reference": "Medication/mii-exa-mtb-medikation-trametinib"
},
"description": "Trametinib (Dabrafenib/Trametinib-Kombinationstherapie)",
"exampleBoolean": true
}, {
"name": "mii-exa-mtb-patient",
"reference": {
"reference": "Patient/mii-exa-mtb-patient"
},
"description": "Beispiel-Patient für Therapieplan mit Therapieempfehlung für Dabrafenib/Trametinib-Kombinationstherapie",
"exampleBoolean": true
}, {
"name": "mii-exa-mtb-therapieempfehlung-dabrafenib",
"reference": {
"reference": "MedicationRequest/mii-exa-mtb-therapieempfehlung-dabrafenib"
},
"description": "Therapieempfehlung für Dabrafenib",
"exampleCanonical": "https://www.medizininformatik-initiative.de/fhir/ext/modul-mtb/StructureDefinition/mii-pr-mtb-therapieempfehlung"
}, {
"name": "mii-exa-mtb-therapieempfehlung-kombinationstherapie",
"reference": {
"reference": "RequestGroup/mii-exa-mtb-therapieempfehlung-kombinationstherapie"
},
"description": "Therapieempfehlung für Dabrafenib/Trametinib-Kombinationstherapie",
"exampleCanonical": "https://www.medizininformatik-initiative.de/fhir/ext/modul-mtb/StructureDefinition/mii-pr-mtb-therapieempfehlung-kombination"
}, {
"name": "mii-exa-mtb-therapieempfehlung-trametinib",
"reference": {
"reference": "MedicationRequest/mii-exa-mtb-therapieempfehlung-trametinib"
},
"description": "Therapieempfehlung für Trametinib",
"exampleCanonical": "https://www.medizininformatik-initiative.de/fhir/ext/modul-mtb/StructureDefinition/mii-pr-mtb-therapieempfehlung"
}, {
"name": "mii-exa-mtb-therapieplan-kombinationstherapie",
"reference": {
"reference": "CarePlan/mii-exa-mtb-therapieplan-kombinationstherapie"
},
"description": "Therapieplan mit Therapieempfehlung für Dabrafenib/Trametinib-Kombinationstherapie",
"exampleCanonical": "https://www.medizininformatik-initiative.de/fhir/ext/modul-mtb/StructureDefinition/mii-pr-mtb-therapieplan"
}, {
"name": "Mirvetuximab soravtansine",
"reference": {
"reference": "MedicationRequest/mii-exa-mtb-medication-request-mirvetuximab"
},
"description": "Therapieempfehlung: Mirvetuximab soravtansine, Priorität: 1, Evidenzgrad: m1A",
"exampleCanonical": "https://www.medizininformatik-initiative.de/fhir/ext/modul-mtb/StructureDefinition/mii-pr-mtb-therapieempfehlung"
}, {
"name": "MTB-Behandlungsepisode Kim Musterperson",
"reference": {
"reference": "ClinicalImpression/mii-exa-mtb-kim-musterperson-behandlungsepisode"
},
"description": "Molekulares Tumorboard-Behandlungsepisode von Kim Musterperson ab 01.03.2022",
"exampleCanonical": "https://www.medizininformatik-initiative.de/fhir/ext/modul-mtb/StructureDefinition/mii-pr-mtb-behandlungsepisode"
}, {
"name": "MTB-Beschluss Kim Musterperson",
"reference": {
"reference": "CarePlan/mii-exa-mtb-kim-musterperson-therapieplan"
},
"description": "Beschluss MTB-Fall Kim Musterperson vom 28.03.2023",
"exampleCanonical": "https://www.medizininformatik-initiative.de/fhir/ext/modul-mtb/StructureDefinition/mii-pr-mtb-therapieplan"
}, {
"name": "MTB-NGS-Bericht Kim Musterperson",
"reference": {
"reference": "DiagnosticReport/mii-exa-mtb-kim-musterperson-ngs-bericht"
},
"description": "Ergebnisse des NGS-Bericht von Kim Musterperson",
"exampleCanonical": "https://www.medizininformatik-initiative.de/fhir/ext/modul-mtb/StructureDefinition/mii-pr-mtb-ngs-bericht"
}, {
"name": "MTB-NGS-Bericht Kim Musterperson",
"reference": {
"reference": "Procedure/mii-exa-mtb-kim-musterperson-genomic-study"
},
"description": "Details zur Durchführung NGS-Bericht von Kim Musterperson",
"exampleCanonical": "https://www.medizininformatik-initiative.de/fhir/ext/modul-mtb/StructureDefinition/mii-pr-mtb-genomic-study"
}, {
"name": "MTB-NGS-Bericht Kim Musterperson",
"reference": {
"reference": "Procedure/mii-exa-mtb-kim-musterperson-genomic-study-analysis-1"
},
"description": "Details zur Analyse NGS-Bericht von Kim Musterperson - TSO500",
"exampleCanonical": "https://www.medizininformatik-initiative.de/fhir/ext/modul-mtb/StructureDefinition/genomic-study-analysis"
}, {
"name": "MTB-NGS-Bericht Kim Musterperson",
"reference": {
"reference": "Procedure/mii-exa-mtb-kim-musterperson-genomic-study-analysis-3"
},
"description": "Diagnostische Prozeduren MolPatho-Bericht von Kim Musterperson - Immunhistochemie",
"exampleCanonical": "https://www.medizininformatik-initiative.de/fhir/ext/modul-mtb/StructureDefinition/genomic-study-analysis"
}, {
"name": "MTB-NGS-Bericht Kim Musterperson HLA Status",
"reference": {
"reference": "Procedure/mii-exa-mtb-kim-musterperson-genomic-study-analysis-2"
},
"description": "Diagnostische Prozeduren NGS-Bericht von Kim Musterperson - HLA-Statu - keine näheren Angaben weil Beispiel",
"exampleCanonical": "https://www.medizininformatik-initiative.de/fhir/ext/modul-mtb/StructureDefinition/genomic-study-analysis"
}, {
"name": "MTBChemo1MedicationStatement1",
"reference": {
"reference": "MedicationStatement/MTBChemo1MedicationStatement1"
},
"exampleBoolean": true
}, {
"name": "MTBChemo1MedicationStatement1-1",
"reference": {
"reference": "MedicationStatement/MTBChemo1MedicationStatement1-1"
},
"exampleBoolean": true
}, {
"name": "MTBChemo1MedicationStatement1-2",
"reference": {
"reference": "MedicationStatement/MTBChemo1MedicationStatement1-2"
},
"exampleBoolean": true
}, {
"name": "MTBChemo1MedicationStatement2",
"reference": {
"reference": "MedicationStatement/MTBChemo1MedicationStatement2"
},
"exampleBoolean": true
}, {
"name": "MTBChemo1MedicationStatement2-1",
"reference": {
"reference": "MedicationStatement/MTBChemo1MedicationStatement2-1"
},
"exampleBoolean": true
}, {
"name": "MTBChemo1MedicationStatement2-2",
"reference": {
"reference": "MedicationStatement/MTBChemo1MedicationStatement2-2"
},
"exampleBoolean": true
}, {
"name": "MTBChemo1MedicationStatement3",
"reference": {
"reference": "MedicationStatement/MTBChemo1MedicationStatement3"
},
"exampleBoolean": true
}, {
"name": "MTBChemo1MedicationStatement3-1",
"reference": {
"reference": "MedicationStatement/MTBChemo1MedicationStatement3-1"
},
"exampleBoolean": true
}, {
"name": "MTBChemo1MedicationStatement3-2",
"reference": {
"reference": "MedicationStatement/MTBChemo1MedicationStatement3-2"
},
"exampleBoolean": true
}, {
"name": "MTBChemo1MedicationStatement4",
"reference": {
"reference": "MedicationStatement/MTBChemo1MedicationStatement4"
},
"exampleBoolean": true
}, {
"name": "MTBChemo1MedicationStatement4-1",
"reference": {
"reference": "MedicationStatement/MTBChemo1MedicationStatement4-1"
},
"exampleBoolean": true
}, {
"name": "MTBChemo1MedicationStatement4-2",
"reference": {
"reference": "MedicationStatement/MTBChemo1MedicationStatement4-2"
},
"exampleBoolean": true
}, {
"name": "MTBChemo1MedicationStatement5",
"reference": {
"reference": "MedicationStatement/MTBChemo1MedicationStatement5"
},
"exampleBoolean": true
}, {
"name": "MTBChemo1MedicationStatement5-1",
"reference": {
"reference": "MedicationStatement/MTBChemo1MedicationStatement5-1"
},
"exampleBoolean": true
}, {
"name": "MTBChemo1MedicationStatement5-2",
"reference": {
"reference": "MedicationStatement/MTBChemo1MedicationStatement5-2"
},
"exampleBoolean": true
}, {
"name": "MTBChemo1MedicationStatement6",
"reference": {
"reference": "MedicationStatement/MTBChemo1MedicationStatement6"
},
"exampleBoolean": true
}, {
"name": "MTBChemo1MedicationStatement6-1",
"reference": {
"reference": "MedicationStatement/MTBChemo1MedicationStatement6-1"
},
"exampleBoolean": true
}, {
"name": "MTBChemo1MedicationStatement6-2",
"reference": {
"reference": "MedicationStatement/MTBChemo1MedicationStatement6-2"
},
"exampleBoolean": true
}, {
"name": "MTBChemo1Procedure",
"reference": {
"reference": "Procedure/MTBChemo1Procedure"
},
"description": "Carboplatin AUC5 d1, pegliposomales Doxorubicin 30 mg/m2, d1, Wdh. d28; Sechs Zyklen ab 04.01.2023",
"exampleCanonical": "https://www.medizininformatik-initiative.de/fhir/ext/modul-mtb/StructureDefinition/mii-pr-mtb-systemische-vortherapie"
}, {
"name": "MTBChemo2MedicationStatement1",
"reference": {
"reference": "MedicationStatement/MTBChemo2MedicationStatement1"
},
"exampleBoolean": true
}, {
"name": "MTBChemo2MedicationStatement2",
"reference": {
"reference": "MedicationStatement/MTBChemo2MedicationStatement2"
},
"exampleBoolean": true
}, {
"name": "MTBChemo2MedicationStatement3",
"reference": {
"reference": "MedicationStatement/MTBChemo2MedicationStatement3"
},
"exampleBoolean": true
}, {
"name": "MTBChemo2MedicationStatement4",
"reference": {
"reference": "MedicationStatement/MTBChemo2MedicationStatement4"
},
"exampleBoolean": true
}, {
"name": "MTBChemo2MedicationStatement5",
"reference": {
"reference": "MedicationStatement/MTBChemo2MedicationStatement5"
},
"exampleBoolean": true
}, {
"name": "MTBChemo2MedicationStatement6",
"reference": {
"reference": "MedicationStatement/MTBChemo2MedicationStatement6"
},
"exampleBoolean": true
}, {
"name": "MTBChemo2Procedure",
"reference": {
"reference": "Procedure/MTBChemo2Procedure"
},
"description": "Mirvetuximab soravtansine 6mg/kg KG, Wdh d22; Sechs Zyklen ab 24.06.2023",
"exampleCanonical": "https://www.medizininformatik-initiative.de/fhir/ext/modul-mtb/StructureDefinition/mii-pr-mtb-systemische-vortherapie"
}, {
"name": "NCT04503278 Age Group",
"reference": {
"reference": "Group/mii-exa-mtb-study-cldn6-eligibility-criteria-age-groups"
},
"description": "NCT04503278 Eligibility Criteria Age Group",
"exampleBoolean": true
}, {
"name": "NCT04503278 CLDN6 CAR-T",
"reference": {
"reference": "EvidenceVariable/mii-exa-mtb-study-cldn6-evidence-variable-0"
},
"description": "NCT04503278 CLDN6 CAR-T: Administered as an intravenous (i.v.) infusion",
"exampleBoolean": true
}, {
"name": "NCT04503278 CLDN6 uRNA-LPX/CLDN6 modRNA-LPX",
"reference": {
"reference": "EvidenceVariable/mii-exa-mtb-study-cldn6-evidence-variable-1"
},
"description": "NCT04503278 CLDN6 uRNA-LPX/CLDN6 modRNA-LPX: Administered as an i.v. injection at protocol-specified intervals",
"exampleBoolean": true
}, {
"name": "NCT04503278 Comparison Group: Part 1 - CLDN6 CAR-T",
"reference": {
"reference": "Group/mii-exa-mtb-study-cldn6-comparison-group-0"
},
"description": "NCT04503278 CLDN6 CAR-T: Dose escalation in lymphodepleted patients until the MTD and/or RP2D",
"exampleBoolean": true
}, {
"name": "NCT04503278 Comparison Group: Part 2 Vaccine-modulated - CLDN6 uRNA-LPX/CLDN6 modRNA-LPX",
"reference": {
"reference": "Group/mii-exa-mtb-study-cldn6-comparison-group-1"
},
"description": "Dose escalation until the MTD and/or RP2D",
"exampleBoolean": true
}, {
"name": "NCT04503278 Eligibility Criteria",
"reference": {
"reference": "Group/mii-exa-mtb-study-cldn6-eligibility-criteria"
},
"description": "NCT04503278 Eligibility Criteria",
"exampleBoolean": true
}, {
"name": "NCT04503278 L0",
"reference": {
"reference": "Location/mii-exa-mtb-study-cldn6-location-0"
},
"description": "NCT04503278 Location 0",
"exampleBoolean": true
}, {
"name": "NCT04503278 L1",
"reference": {
"reference": "Location/mii-exa-mtb-study-cldn6-location-1"
},
"description": "NCT04503278 Location 1",
"exampleBoolean": true
}, {
"name": "NCT04503278 L10",
"reference": {
"reference": "Location/mii-exa-mtb-study-cldn6-location-10"
},
"description": "NCT04503278 Location 10",
"exampleBoolean": true
}, {
"name": "NCT04503278 L11",
"reference": {
"reference": "Location/mii-exa-mtb-study-cldn6-location-11"
},
"description": "NCT04503278 Location 11",
"exampleBoolean": true
}, {
"name": "NCT04503278 L2",
"reference": {
"reference": "Location/mii-exa-mtb-study-cldn6-location-2"
},
"description": "NCT04503278 Location 2",
"exampleBoolean": true
}, {
"name": "NCT04503278 L3",
"reference": {
"reference": "Location/mii-exa-mtb-study-cldn6-location-3"
},
"description": "NCT04503278 Location 3",
"exampleBoolean": true
}, {
"name": "NCT04503278 L4",
"reference": {
"reference": "Location/mii-exa-mtb-study-cldn6-location-4"
},
"description": "NCT04503278 Location 4",
"exampleBoolean": true
}, {
"name": "NCT04503278 L5",
"reference": {
"reference": "Location/mii-exa-mtb-study-cldn6-location-5"
},
"description": "NCT04503278 Location 5",
"exampleBoolean": true
}, {
"name": "NCT04503278 L6",
"reference": {
"reference": "Location/mii-exa-mtb-study-cldn6-location-6"
},
"description": "NCT04503278 Location 6",
"exampleBoolean": true
}, {
"name": "NCT04503278 L7",
"reference": {
"reference": "Location/mii-exa-mtb-study-cldn6-location-7"
},
"description": "NCT04503278 Location 7",
"exampleBoolean": true
}, {
"name": "NCT04503278 L8",
"reference": {
"reference": "Location/mii-exa-mtb-study-cldn6-location-8"
},
"description": "NCT04503278 Location 8",
"exampleBoolean": true
}, {
"name": "NCT04503278 L9",
"reference": {
"reference": "Location/mii-exa-mtb-study-cldn6-location-9"
},
"description": "NCT04503278 Location 9",
"exampleBoolean": true
}, {
"name": "PatientKimMusterperson",
"reference": {
"reference": "Patient/PatientKimMusterperson"
},
"exampleBoolean": true
}, {
"name": "PatientKimMusterperson-AscitesSpecimen-2",
"reference": {
"reference": "Specimen/PatientKimMusterperson-AscitesSpecimen-2"
},
"exampleBoolean": true
}, {
"name": "PatientKimMusterperson-MolecularPathologyInterpret-0a-Her2neu",
"reference": {
"reference": "Observation/PatientKimMusterperson-MolecularPathologyInterpret-0a-Her2neu"
},
"exampleCanonical": "https://www.medizininformatik-initiative.de/fhir/ext/modul-mtb/StructureDefinition/mii-pr-mtb-immunohistochemistry"
}, {
"name": "PatientKimMusterperson-MolecularPathologyObservation-0a-Her2neu",
"reference": {
"reference": "Observation/PatientKimMusterperson-MolecularPathologyObservation-0a-Her2neu"
},
"exampleCanonical": "https://www.medizininformatik-initiative.de/fhir/ext/modul-mtb/StructureDefinition/mii-pr-mtb-immunohistochemistry"
}, {
"name": "PatientKimMusterperson-MolecularPathologyObservation-0b-Folat-Ra",
"reference": {
"reference": "Observation/PatientKimMusterperson-MolecularPathologyObservation-0b-Folat-Ra"
},
"exampleCanonical": "https://www.medizininformatik-initiative.de/fhir/ext/modul-mtb/StructureDefinition/mii-pr-mtb-immunohistochemistry"
}, {
"name": "PatientKimMusterperson-MolecularPathologyObservation-0c-Trop2",
"reference": {
"reference": "Observation/PatientKimMusterperson-MolecularPathologyObservation-0c-Trop2"
},
"exampleCanonical": "https://www.medizininformatik-initiative.de/fhir/ext/modul-mtb/StructureDefinition/mii-pr-mtb-immunohistochemistry"
}, {
"name": "PatientKimMusterperson-MolecularPathologyObservation-1-CA125",
"reference": {
"reference": "Observation/PatientKimMusterperson-MolecularPathologyObservation-1-CA125"
},
"exampleCanonical": "https://www.medizininformatik-initiative.de/fhir/ext/modul-mtb/StructureDefinition/mii-pr-mtb-immunohistochemistry"
}, {
"name": "PatientKimMusterperson-MolecularPathologyObservation-2-Pax8",
"reference": {
"reference": "Observation/PatientKimMusterperson-MolecularPathologyObservation-2-Pax8"
},
"exampleCanonical": "https://www.medizininformatik-initiative.de/fhir/ext/modul-mtb/StructureDefinition/mii-pr-mtb-immunohistochemistry"
}, {
"name": "PatientKimMusterperson-MolecularPathologyObservation-3-WT1",
"reference": {
"reference": "Observation/PatientKimMusterperson-MolecularPathologyObservation-3-WT1"
},
"exampleCanonical": "https://www.medizininformatik-initiative.de/fhir/ext/modul-mtb/StructureDefinition/mii-pr-mtb-immunohistochemistry"
}, {
"name": "PatientKimMusterperson-MolecularPathologyObservation-4-ER",
"reference": {
"reference": "Observation/PatientKimMusterperson-MolecularPathologyObservation-4-ER"
},
"exampleCanonical": "https://www.medizininformatik-initiative.de/fhir/ext/modul-mtb/StructureDefinition/mii-pr-mtb-immunohistochemistry"
}, {
"name": "PatientKimMusterperson-MolecularPathologyObservation-5-PR",
"reference": {
"reference": "Observation/PatientKimMusterperson-MolecularPathologyObservation-5-PR"
},
"exampleCanonical": "https://www.medizininformatik-initiative.de/fhir/ext/modul-mtb/StructureDefinition/mii-pr-mtb-immunohistochemistry"
}, {
"name": "PatientKimMusterperson-MolecularPathologyObservation-6-p53",
"reference": {
"reference": "Observation/PatientKimMusterperson-MolecularPathologyObservation-6-p53"
},
"exampleCanonical": "https://www.medizininformatik-initiative.de/fhir/ext/modul-mtb/StructureDefinition/mii-pr-mtb-immunohistochemistry"
}, {
"name": "PatientKimMusterperson-MolecularPathologyObservation-7-p53",
"reference": {
"reference": "Observation/PatientKimMusterperson-MolecularPathologyObservation-7-p53"
},
"exampleCanonical": "https://www.medizininformatik-initiative.de/fhir/ext/modul-mtb/StructureDefinition/mii-pr-mtb-immunohistochemistry"
}, {
"name": "PatientKimMusterperson-MolecularPathologyReport-1",
"reference": {
"reference": "DiagnosticReport/PatientKimMusterperson-MolecularPathologyReport-1"
},
"exampleCanonical": "https://www.medizininformatik-initiative.de/fhir/ext/modul-mtb/StructureDefinition/mii-pr-mtb-molecular-pathology-report"
}, {
"name": "PatientKimMusterperson-Observation-1",
"reference": {
"reference": "Observation/PatientKimMusterperson-Observation-1"
},
"description": "kein Hinweis auf thorakale Metastasierung",
"exampleBoolean": true
}, {
"name": "PatientKimMusterperson-Observation-10",
"reference": {
"reference": "Observation/PatientKimMusterperson-Observation-10"
},
"description": "regrediente Flüssigkeitskollektion am Leberrand, Z.n. atypische Lebersegmentresektion. Darüberhinaus kein Hinweis auf Leberfilialisierung.",
"exampleBoolean": true
}, {
"name": "PatientKimMusterperson-Observation-11",
"reference": {
"reference": "Observation/PatientKimMusterperson-Observation-11"
},
"description": "kein Aszites",
"exampleBoolean": true
}, {
"name": "PatientKimMusterperson-Observation-12",
"reference": {
"reference": "Observation/PatientKimMusterperson-Observation-12"
},
"description": "kein Hinweis auf Lokalrezidiv",
"exampleBoolean": true
}, {
"name": "PatientKimMusterperson-Observation-13",
"reference": {
"reference": "Observation/PatientKimMusterperson-Observation-13"
},
"description": "regrediente Milchglasinfiltrate im linken Oberlappen, somit a.e. atypisch entzündlich.",
"exampleBoolean": true
}, {
"name": "PatientKimMusterperson-Observation-14",
"reference": {
"reference": "Observation/PatientKimMusterperson-Observation-14"
},
"description": "Leicht vermehrter mediastinaler Lymphknotenbesatz ohne Kontrastmittelaufnahme",
"exampleBoolean": true
}, {
"name": "PatientKimMusterperson-Observation-15",
"reference": {
"reference": "Observation/PatientKimMusterperson-Observation-15"
},
"description": "Leicht vermehrter mediastinaler Lymphknotenbesatz ohne pathologische Vergrößerung, Verlaufskontrolle empfohlen",
"exampleBoolean": true
}, {
"name": "PatientKimMusterperson-Observation-16",
"reference": {
"reference": "Observation/PatientKimMusterperson-Observation-16"
},
"description": "progredienter Aszites (ca. 700ml)",
"exampleBoolean": true
}, {
"name": "PatientKimMusterperson-Observation-17",
"reference": {
"reference": "Observation/PatientKimMusterperson-Observation-17"
},
"description": "Peritonealblatt mit zunehmender, unregelmäßiger KM-Aufnahme",
"exampleBoolean": true
}, {
"name": "PatientKimMusterperson-Observation-18",
"reference": {
"reference": "Observation/PatientKimMusterperson-Observation-18"
},
"description": "suspekt auf Progress der bekannten Peritonealkarzinose",
"exampleBoolean": true
}, {
"name": "PatientKimMusterperson-Observation-19",
"reference": {
"reference": "Observation/PatientKimMusterperson-Observation-19"
},
"description": "V.a. Lokalrezidiv bei kontrastmittelaufnehmender Raumforderung im kleinen Becken",
"exampleBoolean": true
}, {
"name": "PatientKimMusterperson-Observation-2",
"reference": {
"reference": "Observation/PatientKimMusterperson-Observation-2"
},
"description": "kein Hinweis auf Lokalrezidiv",
"exampleBoolean": true
}, {
"name": "PatientKimMusterperson-Observation-20",
"reference": {
"reference": "Observation/PatientKimMusterperson-Observation-20"
},
"description": "regredienter Aszites",
"exampleBoolean": true
}, {
"name": "PatientKimMusterperson-Observation-21",
"reference": {
"reference": "Observation/PatientKimMusterperson-Observation-21"
},
"description": "rückläufige KM-Aufnahme der lokalrezidivsuspekten Raumforderung im kleinen Becken",
"exampleBoolean": true
}, {
"name": "PatientKimMusterperson-Observation-22",
"reference": {
"reference": "Observation/PatientKimMusterperson-Observation-22"
},
"description": "noch flaue, aber insgesamt regrediente KM-Aufnhame der zahlenmäßig vermehrten LK im Mediastinum",
"exampleBoolean": true
}, {
"name": "PatientKimMusterperson-Observation-23",
"reference": {
"reference": "Observation/PatientKimMusterperson-Observation-23"
},
"description": "keine neue metastasensuspekte Läsion",
"exampleBoolean": true
}, {
"name": "PatientKimMusterperson-Observation-24",
"reference": {
"reference": "Observation/PatientKimMusterperson-Observation-24"
},
"description": "kein Aszites",
"exampleBoolean": true
}, {
"name": "PatientKimMusterperson-Observation-25",
"reference": {
"reference": "Observation/PatientKimMusterperson-Observation-25"
},
"description": "fast vollständig regredientes Lokalrezidiv ohne KM-Aufnahme im kleinen Becken",
"exampleBoolean": true
}, {
"name": "PatientKimMusterperson-Observation-26",
"reference": {
"reference": "Observation/PatientKimMusterperson-Observation-26"
},
"description": "geringer Aszites im kleinen Becken",
"exampleBoolean": true
}, {
"name": "PatientKimMusterperson-Observation-27",
"reference": {
"reference": "Observation/PatientKimMusterperson-Observation-27"
},
"description": "vormals KM-aufnehmendes Lokalrezidiv im kleinen Becken aktuell metrisch nur noch schwer fassbar",
"exampleBoolean": true
}, {
"name": "PatientKimMusterperson-Observation-29",
"reference": {
"reference": "Observation/PatientKimMusterperson-Observation-29"
},
"description": "formal noch vermehrte mediastinale Lymphknoten",
"exampleBoolean": true
}, {
"name": "PatientKimMusterperson-Observation-3",
"reference": {
"reference": "Observation/PatientKimMusterperson-Observation-3"
},
"description": "kein Aszites",
"exampleBoolean": true
}, {
"name": "PatientKimMusterperson-Observation-30",
"reference": {
"reference": "Observation/PatientKimMusterperson-Observation-30"
},
"description": "nicht mehr KM-aufnehmende mediastinale Lymphknoten",
"exampleBoolean": true
}, {
"name": "PatientKimMusterperson-Observation-4",
"reference": {
"reference": "Observation/PatientKimMusterperson-Observation-4"
},
"description": "Z.n. atypischer Lebersegmentresektion, kein eindeutiger Hinweis auf Metastasierung. Flüssigkeitskollektion angrenzend DD postoperativ",
"exampleBoolean": true
}, {
"name": "PatientKimMusterperson-Observation-5",
"reference": {
"reference": "Observation/PatientKimMusterperson-Observation-5"
},
"description": "konstante Flüssigkeitskollektion angrenzend bei Z.n. atpyischer Lebersegmentresktion, a.e. postoperativ",
"exampleBoolean": true
}, {
"name": "PatientKimMusterperson-Observation-6",
"reference": {
"reference": "Observation/PatientKimMusterperson-Observation-6"
},
"description": "kein Aszites",
"exampleBoolean": true
}, {
"name": "PatientKimMusterperson-Observation-7",
"reference": {
"reference": "Observation/PatientKimMusterperson-Observation-7"
},
"description": "kein Hinweis auf Lokalrezidiv",
"exampleBoolean": true
}, {
"name": "PatientKimMusterperson-Observation-8",
"reference": {
"reference": "Observation/PatientKimMusterperson-Observation-8"
},
"description": "im linken Oberlappen der Lunge diskrete milchglasartige Trübung DD atypisch entzündlich, klinische Korrelation empfohlen, darüber hinaus kein Hinweis auf thorakale Filiae",
"exampleBoolean": true
}, {
"name": "PatientKimMusterperson-Observation-9",
"reference": {
"reference": "Observation/PatientKimMusterperson-Observation-9"
},
"description": "regrediente Flüssigkeitskollektion am Leberrand, Z.n. atypische Lebersegmentresektion. Darüberhinaus kein Hinweis auf Leberfilialisierung.",
"exampleBoolean": true
}, {
"name": "PatientKimMusterperson-Procedure-1",
"reference": {
"reference": "Procedure/PatientKimMusterperson-Procedure-1"
},
"description": "20.04.22 CT T/A",
"exampleBoolean": true
}, {
"name": "PatientKimMusterperson-Procedure-2",
"reference": {
"reference": "Procedure/PatientKimMusterperson-Procedure-2"
},
"description": "15.07.22 CT T/A",
"exampleBoolean": true
}, {
"name": "PatientKimMusterperson-Procedure-3",
"reference": {
"reference": "Procedure/PatientKimMusterperson-Procedure-3"
},
"description": "19.10.22 CT T/A",
"exampleBoolean": true
}, {
"name": "PatientKimMusterperson-Procedure-4",
"reference": {
"reference": "Procedure/PatientKimMusterperson-Procedure-4"
},
"description": "19.12.22 CT T/A",
"exampleBoolean": true
}, {
"name": "PatientKimMusterperson-Procedure-5",
"reference": {
"reference": "Procedure/PatientKimMusterperson-Procedure-5"
},
"description": "20.03.2023 CT T/A",
"exampleBoolean": true
}, {
"name": "PatientKimMusterperson-Procedure-6",
"reference": {
"reference": "Procedure/PatientKimMusterperson-Procedure-6"
},
"description": "20.08.2023 CT T/A",
"exampleBoolean": true
}, {
"name": "PatientKimMusterperson-Procedure-7",
"reference": {
"reference": "Procedure/PatientKimMusterperson-Procedure-7"
},
"description": "22.10.2023 CT T/A",
"exampleBoolean": true
}, {
"name": "PatientKimMusterperson-Specimen-1",
"reference": {
"reference": "Specimen/PatientKimMusterperson-Specimen-1"
},
"description": "02.01.2023 Histologie (Z 230201/23)",
"exampleBoolean": true
}, {
"name": "Phase 1/2 CLDN6 CAR-T-Zell-Studie",
"reference": {
"reference": "ServiceRequest/mii-exa-mtb-study-request-cldn6"
},
"description": "Studieneinschlussempfehlung: Phase 1/2 CLDN6 CAR-T-Zell-Studie, Priorität: 2.1",
"exampleCanonical": "https://www.medizininformatik-initiative.de/fhir/ext/modul-mtb/StructureDefinition/mii-pr-mtb-studieneinschluss-anfrage"
}, {
"name": "PIK3R1 Einfache Variante",
"reference": {
"reference": "Observation/mii-exa-mtb-kim-musterperson-EinfacheVariante-PIK3R1"
},
"description": "Nachweis einer PIK3R1-Mutation",
"exampleCanonical": "https://www.medizininformatik-initiative.de/fhir/ext/modul-mtb/StructureDefinition/mii-pr-mtb-einfache-variante"
}, {
"name": "PIK3R1 Therapeutische Implikation",
"reference": {
"reference": "Observation/mii-exa-mtb-kim-musterperson-TherapeutischeImplikation-PIK3R1"
},
"description": "Therapeutische Bedeutung der festgestellten PIK3R1 Mutation",
"exampleBoolean": true
}, {
"name": "TEDOVA",
"reference": {
"reference": "ResearchStudy/mii-exa-mtb-study-tedova"
},
"description": "Studie: TEDOVA - OSE2101 (Neo-Epitop-Vakzin)+/- Pembrolizumab vs. BSC in Platin-sensitiven rez. Ov-CA",
"exampleCanonical": "https://www.medizininformatik-initiative.de/fhir/ext/modul-mtb/StructureDefinition/mii-pr-mtb-studie"
}, {
"name": "TEDOVA",
"reference": {
"reference": "ServiceRequest/mii-exa-mtb-study-request-tedova"
},
"description": "Studieeinschlussempfehlung: TEDOVA - OSE2101 (Neo-Epitop-Vakzin)+/- Pembrolizumab vs. BSC in Platin-sensitiven rez. Ov-CA",
"exampleCanonical": "https://www.medizininformatik-initiative.de/fhir/ext/modul-mtb/StructureDefinition/mii-pr-mtb-studieneinschluss-anfrage"
}, {
"name": "TP53 Diagnostische Implikation",
"reference": {
"reference": "Observation/mii-exa-mtb-kim-musterperson-DiagnostischeImplikation-TP53"
},
"description": "Diagnostische Bedeutung der festgestellten TP53 Mutation",
"exampleBoolean": true
}, {
"name": "TP53 Einfache Variante",
"reference": {
"reference": "Observation/mii-exa-mtb-kim-musterperson-EinfacheVariante-TP53"
},
"description": "Nachweis einer pathogenen TP53-Mutation",
"exampleCanonical": "https://www.medizininformatik-initiative.de/fhir/ext/modul-mtb/StructureDefinition/mii-pr-mtb-einfache-variante"
}, {
"name": "Trastuzumab deruxtecan",
"reference": {
"reference": "MedicationRequest/mii-exa-mtb-medication-requestion-trastuzumab-deruxtecan"
},
"description": "Therapieempfehlung: Trastuzumab deruxtecan, Priorität: 3, Evidenzgrad: m1B",
"exampleCanonical": "https://www.medizininformatik-initiative.de/fhir/ext/modul-mtb/StructureDefinition/mii-pr-mtb-therapieempfehlung"
} ],
"parameter": [ {
"code": "copyrightyear",
"value": "2024+"
}, {
"code": "releaselabel",
"value": "ci-build"
} ]
},
"date": null,
"publisher": "Medizininformatik-Initiative",
"fhirVersion": [ "4.0.1" ],
"license": "CC0-1.0",
"jurisdiction": [ {
"coding": [ {
"code": "276",
"system": "http://unstats.un.org/unsd/methods/m49/m49.htm"
} ]
} ],
"dependsOn": [ {
"id": "de_medizininformatikinitiative_kerndatensatz_biobank",
"uri": "http://fhir.org/packages/de.medizininformatikinitiative.kerndatensatz.biobank/ImplementationGuide/de.medizininformatikinitiative.kerndatensatz.biobank",
"version": "2025.0.3",
"packageId": "de.medizininformatikinitiative.kerndatensatz.biobank"
}, {
"id": "de_medizininformatikinitiative_kerndatensatz_consent",
"uri": "http://fhir.org/packages/de.medizininformatikinitiative.kerndatensatz.consent/ImplementationGuide/de.medizininformatikinitiative.kerndatensatz.consent",
"version": "2025.0.0",
"packageId": "de.medizininformatikinitiative.kerndatensatz.consent"
}, {
"id": "de_medizininformatikinitiative_kerndatensatz_diagnose",
"uri": "https://www.medizininformatik-initiative.de/fhir/core/modul-diagnose/ImplementationGuide/mii-ig-diagnose",
"version": "2025.0.0",
"packageId": "de.medizininformatikinitiative.kerndatensatz.diagnose"
}, {
"id": "de_medizininformatikinitiative_kerndatensatz_fall",
"uri": "https://www.medizininformatik-initiative.de/fhir/core/modul-fall/ImplementationGuide/mii-ig-fall",
"version": "2025.0.0",
"packageId": "de.medizininformatikinitiative.kerndatensatz.fall"
}, {
"id": "de_medizininformatikinitiative_kerndatensatz_medikation",
"uri": "https://www.medizininformatik-initiative.de/fhir/core/modul-medikation/ImplementationGuide/mii-ig-medikation",
"version": "2025.0.0",
"packageId": "de.medizininformatikinitiative.kerndatensatz.medikation"
}, {
"id": "de_medizininformatikinitiative_kerndatensatz_meta",
"uri": "http://fhir.org/packages/de.medizininformatikinitiative.kerndatensatz.meta/ImplementationGuide/de.medizininformatikinitiative.kerndatensatz.meta",
"version": "2025.0.0",
"packageId": "de.medizininformatikinitiative.kerndatensatz.meta"
}, {
"id": "de_medizininformatikinitiative_kerndatensatz_molgen",
"uri": "http://fhir.org/packages/de.medizininformatikinitiative.kerndatensatz.molgen/ImplementationGuide/de.medizininformatikinitiative.kerndatensatz.molgen",
"version": "2025.0.0",
"packageId": "de.medizininformatikinitiative.kerndatensatz.molgen"
}, {
"id": "de_medizininformatikinitiative_kerndatensatz_onkologie",
"uri": "http://fhir.org/packages/de.medizininformatikinitiative.kerndatensatz.onkologie/ImplementationGuide/de.medizininformatikinitiative.kerndatensatz.onkologie",
"version": "2025.0.3",
"packageId": "de.medizininformatikinitiative.kerndatensatz.onkologie"
}, {
"id": "de_medizininformatikinitiative_kerndatensatz_patho",
"uri": "http://fhir.org/packages/de.medizininformatikinitiative.kerndatensatz.patho/ImplementationGuide/de.medizininformatikinitiative.kerndatensatz.patho",
"version": "2025.0.2",
"packageId": "de.medizininformatikinitiative.kerndatensatz.patho"
}, {
"id": "de_medizininformatikinitiative_kerndatensatz_person",
"uri": "https://www.medizininformatik-initiative.de/fhir/core/modul-person/ImplementationGuide/mii-ig-person",
"version": "2025.0.0",
"packageId": "de.medizininformatikinitiative.kerndatensatz.person"
}, {
"id": "de_medizininformatikinitiative_kerndatensatz_prozedur",
"uri": "https://www.medizininformatik-initiative.de/fhir/core/modul-prozedur/ImplementationGuide/mii-ig-prozedur",
"version": "2025.0.0",
"packageId": "de.medizininformatikinitiative.kerndatensatz.prozedur"
}, {
"id": "de_medizininformatikinitiative_kerndatensatz_studie",
"uri": "http://fhir.org/packages/de.medizininformatikinitiative.kerndatensatz.studie/ImplementationGuide/de.medizininformatikinitiative.kerndatensatz.studie",
"version": "2025.0.0",
"packageId": "de.medizininformatikinitiative.kerndatensatz.studie"
}, {
"id": "hl7_fhir_uv_genomics_reporting",
"uri": "http://hl7.org/fhir/uv/genomics-reporting/ImplementationGuide/hl7.fhir.uv.genomics-reporting",
"version": "3.0.0",
"packageId": "hl7.fhir.uv.genomics-reporting"
} ],
"name": "MII_IG_MTB_DE",
"type": null,
"experimental": null,
"resourceType": "ImplementationGuide",
"title": "MII IG Molekulares Tumorboard",
"package_version": "2025.0.0-ballot-alpha.1",
"status": "draft",
"language": "de-DE",
"id": "84aacf4c-c997-490a-be37-a03e50fba7fb",
"kind": null,
"url": "https://www.medizininformatik-initiative.de/fhir/ext/modul-mtb/ImplementationGuide/mii-kerndatensatzmodul-molekulares-tumorboard",
"version": "2024.0.0-alpha",
"packageId": "mii-kerndatensatzmodul-molekulares-tumorboard",
"contact": [ {
"name": "Medizininformatik-Initiative",
"telecom": [ {
"value": "https://www.medizininformatik-initiative.de",
"system": "url"
} ]
} ]
}